J&J: positive data for Tremfya in Crohn's disease

(CercleFinance.com) - Johnson & Johnson presents a Phase 3 study of Tremfya (guselkumab): data showed 'significant' results in the treatment of Crohn's disease (CD).


At 48 weeks, the study showed a clinical remission rate of 60% for a maintenance dose of 100 mg every eight weeks and 66.1% for 200 mg every four weeks, compared with 17.1% in the placebo group.

In addition, 41.3% of treated patients showed an endoscopic response.

The laboratory reports that Tremfya has received FDA approval for the treatment of active ulcerative colitis, and is awaiting approval for Crohn's disease.

Copyright (c) 2024 CercleFinance.com. All rights reserved.